Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Meloxicam Tablets vs Capsules
NCT02180490Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2002
- Primary completion
- Jul 2002
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of meloxicam in osteoarthritis (OA) and rheumatoid arthritis (RA) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum observed concentration of the analyte in plasma up to 60 hours and Area under the concentration time curve of the analyte in plasma from zero time to 60 hours. Started May 2002; status: completed.
02
Drugs
meloxicam
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02180490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02180490.